editorial | Q871232 |
scholarly article | Q13442814 |
P356 | DOI | 10.1093/ANNONC/MDX215 |
P8608 | Fatcat ID | release_6bfzma2kcvdufenlv74vc45asm |
P698 | PubMed publication ID | 28633466 |
P50 | author | Christos M. Hatzis | Q57009658 |
P2093 | author name string | L Pusztai | |
B Szekely | |||
P2860 | cites work | Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. | Q41471514 |
European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? | Q41523908 | ||
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. | Q42921828 | ||
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. | Q52907227 | ||
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. | Q54534083 | ||
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. | Q55071239 | ||
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis | Q35935516 | ||
Bevacizumab added to neoadjuvant chemotherapy for breast cancer | Q36106083 | ||
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial | Q36219254 | ||
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer | Q37131869 | ||
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial | Q38443954 | ||
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype | Q39109484 | ||
Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. | Q40065597 | ||
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women | Q40379855 | ||
P433 | issue | 8 | |
P304 | page(s) | 1681-1683 | |
P577 | publication date | 2017-08-01 | |
P1433 | published in | Annals of Oncology | Q326122 |
P1476 | title | Is complete response the answer? | |
P478 | volume | 28 |
Search more.